Cargando…
Reassessing the Potential of Myb-targeted Anti-cancer Therapy
Transcription factor MYB is essential for the tumorigenesis of multiple cancers, especially leukemia, breast cancer, colon cancer, adenoid cystic carcinoma and brain cancer. Thus, MYB has been regarded as an attractive target for tumor therapy. However, pioneer studies of antisense oligodeoxynucleot...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907674/ https://www.ncbi.nlm.nih.gov/pubmed/29675107 http://dx.doi.org/10.7150/jca.23992 |
_version_ | 1783315581879975936 |
---|---|
author | Liu, Xiaofeng Xu, Yunxiao Han, Liping Yi, Yan |
author_facet | Liu, Xiaofeng Xu, Yunxiao Han, Liping Yi, Yan |
author_sort | Liu, Xiaofeng |
collection | PubMed |
description | Transcription factor MYB is essential for the tumorigenesis of multiple cancers, especially leukemia, breast cancer, colon cancer, adenoid cystic carcinoma and brain cancer. Thus, MYB has been regarded as an attractive target for tumor therapy. However, pioneer studies of antisense oligodeoxynucleotides against MYB, which were launched three decades ago in leukemia therapy, were discontinued because of their unsatisfactory clinical outcomes. In recent years, the roles of MYB in tumor transformation have become increasingly clear. Moreover, the regulatory mechanisms of MYB, such as the vital effects of MYB co-regulators on MYB activity and of transcriptional elongation on MYB expression, have been unveiled. These observations have underpinned novel approaches in inhibiting MYB. This review discusses the structure, function and regulation of MYB, focusing on recent insights into MYB-associated oncogenesis and how MYB-targeted therapeutics can be explored. Additionally, the main MYB-targeted therapies, including novel genetic therapy, RNA interference, microRNAs and low-molecular-weight compounds, which are especially promising inhibitors that target MYB co-regulators and transcriptional elongation, are described, and their prospects are assessed. |
format | Online Article Text |
id | pubmed-5907674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-59076742018-04-19 Reassessing the Potential of Myb-targeted Anti-cancer Therapy Liu, Xiaofeng Xu, Yunxiao Han, Liping Yi, Yan J Cancer Review Transcription factor MYB is essential for the tumorigenesis of multiple cancers, especially leukemia, breast cancer, colon cancer, adenoid cystic carcinoma and brain cancer. Thus, MYB has been regarded as an attractive target for tumor therapy. However, pioneer studies of antisense oligodeoxynucleotides against MYB, which were launched three decades ago in leukemia therapy, were discontinued because of their unsatisfactory clinical outcomes. In recent years, the roles of MYB in tumor transformation have become increasingly clear. Moreover, the regulatory mechanisms of MYB, such as the vital effects of MYB co-regulators on MYB activity and of transcriptional elongation on MYB expression, have been unveiled. These observations have underpinned novel approaches in inhibiting MYB. This review discusses the structure, function and regulation of MYB, focusing on recent insights into MYB-associated oncogenesis and how MYB-targeted therapeutics can be explored. Additionally, the main MYB-targeted therapies, including novel genetic therapy, RNA interference, microRNAs and low-molecular-weight compounds, which are especially promising inhibitors that target MYB co-regulators and transcriptional elongation, are described, and their prospects are assessed. Ivyspring International Publisher 2018-03-15 /pmc/articles/PMC5907674/ /pubmed/29675107 http://dx.doi.org/10.7150/jca.23992 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Liu, Xiaofeng Xu, Yunxiao Han, Liping Yi, Yan Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title | Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title_full | Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title_fullStr | Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title_full_unstemmed | Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title_short | Reassessing the Potential of Myb-targeted Anti-cancer Therapy |
title_sort | reassessing the potential of myb-targeted anti-cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907674/ https://www.ncbi.nlm.nih.gov/pubmed/29675107 http://dx.doi.org/10.7150/jca.23992 |
work_keys_str_mv | AT liuxiaofeng reassessingthepotentialofmybtargetedanticancertherapy AT xuyunxiao reassessingthepotentialofmybtargetedanticancertherapy AT hanliping reassessingthepotentialofmybtargetedanticancertherapy AT yiyan reassessingthepotentialofmybtargetedanticancertherapy |